Cervical Cancer
Conditions
Brief summary
Based on the Phase I trial completed by the sponsor, the Phase II clinical trial aims to investigate the effectiveness and safety of image guidance volume-modulated arc radiation therapy concurrently with Nab-Paclitaxel plus Cisplatin for patients with locally advanced cervical cancer.
Interventions
RADIATIONradiotherapy
Image guidance volume modulated arc therapy included 50.4 Gy in 28 fractions to the pelvis and 59.4 Gy simultaneous boost in 28 fractions to involved pelvic and para-aortic lymph nodes, and subsequent high-dose-rate intracavitary brachytherapy at a total dose of 30.0-36.0 Gy in 5-6 fractions, twice a week.
DRUGNab paclitaxel
Concurrent chemotherapy regimen included weekly cisplatin (40 mg/m\^2) and weekly nab-paclitaxel at escalating doses (33 mg/m\^2 per week).
DRUGCisplatin
Concurrent chemotherapy regimen included weekly cisplatin (40 mg/m\^2) and weekly nab-paclitaxel at escalating doses (33 mg/m\^2 per week).
Sponsors
Jilin Provincial Tumor Hospital
Affiliated Hospital of Hebei University
Hebei Medical University Fourth Hospital
Peking University Third Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Radiation Therapy Concurrently With Nab-Paclitaxel Plus Cisplatin
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* (1) Stage IB3 to IVA disease based on the 2018 International Federation of Gynecology and Obstetrics (FIGO) system; * (2) Eastern Cooperative Oncology Group at 2 or less; * (3) Life expectancy of greater than 3 months; * (4) Left ventricular ejection fraction at ≥55%; * (5) Neutrophil count at ≥1500/mm\^3, platelet count at ≥100,000/mm\^3 or hemoglobin at ≥9.0 g/dL; * (6) Serum creatinine at \<1.5 times the upper limit of the normal reference range; * (7) Alanine transaminase or aspartate aminotransferase at \>2.5 times the upper limit of the normal reference range; * (8) Non pregnant or lactating women; * (9) Women of childbearing age willing to adopt reliable contraceptive measures; * (10) Sign informed consent form.
Exclusion criteria
* (1) Individuals who have previously received chemotherapy with albumin bound paclitaxel; * (2) Individuals who have previously received abdominal or pelvic radiation therapy; * (3) Individuals who have received neoadjuvant chemotherapy or targeted, immunotherapy, and other anti-tumor treatments prior to concurrent chemoradiotherapy and chemotherapy; * (4) Individuals with central nervous system diseases or brain metastases； * (5) Other malignant tumors other than cervical cancer have appeared within the past 5 years; * (6) Previously experienced sensory or motor neuropathy (Grade ≥ 2) ; * (7) The researchers evaluate that the uncontrolled serious medical diseases that will affect the ability of the participants to receive the treatment of the clinical trial, such as complicated with serious medical diseases, including serious heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, uncontrolled infection, active peptic ulcer, etc; * (8) known to be allergic to paclitaxel; * (9) Received other experimental drugs or participated in clinical studies for other anti-cancer treatment purposes within 30 days of the first chemotherapy administration; * (10) Serious infections occurring within 4 weeks prior to the start of research treatment, including but not limited to complications of infection requiring hospitalization, bacteremia, or severe pneumonia; * (11) Human immunodeficiency virus (HIV) positive individuals; * (12) Uncontrolled or active viral hepatitis or infection with human immunodeficiency virus; * (13) Researchers determine that it is not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ORR (objective response rate) | the 1, 3, 6, 9, 12 months after the end of the treatment | ORR(objective response rate)=CR (complete response)+PR(partial response)/all participants |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OS | the 1, 2, and 3 years after the end of the treatment | objective response rate |
| PFS | the 1, 2, and 3 years after the end of the treatment | progression-free survival |
| AE | the 1, 3, 6, 9, 12 months, and 2, 3 years after the end of the treatment | adverse events |
| DCR | the 1, 3, 6, 9, 12 months, and 2, 3 years after the end of the treatment | disease control rate |
| CBR | the 1, 3, 6, 9, 12 months, and 2, 3 years after the end of the treatment | clinical benefit rate |
| DOR | the 1, 3, 6, 9, 12 months, and 2, 3 years after the end of the treatment | duration of response |
Contacts
Primary ContactPing Jiang, doctor
Outcome results
None listed